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Summary
Objective: TGF is a potent stimulator of cell growth in cultured rat articular chondrocytes (CRAC). The stimulatory effect is mediated through
the immediate induction of c-fos gene by activating ERK of MAPK. The present study was undertaken to investigate the upstream regulators
involved in TGF-induced ERK activation in CRAC and to compare the results with the events in HepG2 cells.
Results: In vitro kinase and trans-reporting assays showed that TGF preferentially activated ERK and JNK pathways in CRAC and HepG2,
respectively. ERK activation in CRAC was selectively inhibited by PD98059, a MEK inhibitor. Overexpression of wild or active forms of
MEKK1, the upstream activator of ERK and JNK, decreased the TGF-induced 3TP-luciferase activity in CRAC. In contrast, in HepG2
dominant negative form of MEKK1 or SEK1 ligand-dependent reporter activity was diminished. Transfection of TAK1, another MAPKKK, also
positively and negatively regulated 3TP transcriptional activity of HepG2 and CRAC, respectively. Activation of PKA by 8-bromo-cyclic AMP
or forskolin, and inhibition of PKC by calphostin C, resulted in a significant decrease in 3TP activity as well as in vitro ERK kinase activity
in CRAC.
Conclusions: The results indicate that TGF transduces a predominant signal pathway through MEK-ERK-Elk1, independent of MEKK1 or
TAK1 pathway in CRAC. However, in HepG2, activation of MEKK1 and TAK1 is essential for TGF-induced signal transmission. The results
also demonstrated that in CRAC, MEK-ERK pathway activated by TGF is negatively regulated by PKA cascade but transactivated by PKC.
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Transforming growth factor- (TGF) superfamily, com-
posed of TGF, bone morphogenic protein (BMP),
activin and cartilage-derived growth factor (CDGF) sub-
families, regulates a variety of cellular processes including
embryonic differentiation, extracellular matrix formation,
cell proliferation and apoptosis.1–5 In articular cartilage,
TGF plays a critical role in cartilage development, metab-
olism and repair process following cartilage damage. TGF
also stimulates chondrocyte differentiation by accumulating
chondrocyte-specific gene expression such as type II col-
lagen, aggrecan and link protein.6,7 In addition, TGF can
potentially inhibit the release of many catalytic factors,
which are elevated in osteoarthrosis.8,9 Based on the
available evidence obtained from various in vitro and in vivo
studies, TGF is considered a potentially useful agent for
the treatment of arthritic conditions.10,11
TGF binds with a heteromeric complex of the hetero-
geneous type I and type II receptors and transmits signals
through mitogen-activated protein kinase (MAPK) and241Smads pathways.5,12–14 In general, TGF acts as an
inhibitor of cell growth in many cell types, especially epi-
thelial and endothelial cells. Paradoxically, TGF is also a
potent stimulator of proliferation of cultured rat articular
chondrocytes (CRAC).15 We have demonstrated recently
that TGF directly stimulates the growth of chondrocytes by
inducing c-fos.16 We have also shown that TGF specifi-
cally transactivates extracellular regulated kinase (ERK)
but not c-Jun N-terminal kinase (JNK) or p38MAPK of
MAPK cascades, and that ERK activation is required for
TGF-induced proliferation of CRAC.17 These results sug-
gest that specific activation of ERK is a key event leading
to growth stimulation of CRAC. However, the exact
MEK kinase 1 (MEKK1) that regulates MAPK/ERK
kinase (MEK)–ERK pathway is still not clear at this stage.
Furthermore, the mechanisms by which other regulatory
molecules regulate ERK activation remain to be elucidated.
In this study, we investigated the possible signal trans-
duction pathways responsible for activation of an ERK
cascade following TGF stimulation in CRAC. For this, we
examined the role of several upstream regulators that could
modify MAPK cascades in CRAC and HepG2, which was
one of hepatoma cell lines and has often been used for
TGF signaling. Our results demonstrated that TGF trans-
duces intracellular signals preferentially through different
MAPK cascades between CRAC and HepG2; activation of
the MEK–ERK pathway is essential for TGF signaling, but
MEKK1 and TGF-activated kinase (TAK1) negatively
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vation is required for signaling in HepG2. We also showed
the presence of cross-talk pathways from protein kinase A
(PKA) and protein kinase C (PKC) cascades for ERK
activation in CRAC.Materials and methods
MATERIALS
Five-week-old male Sprague–Dawley (SD) rats were
purchased from Charles River Laboratories (Shizuoka,
Japan). Lipofectin reagent, fetal bovine serum (FBS),
DMEM and RPMI medium were obtained from Gibco
Oriental (Tokyo, Japan). Recombinant human TGF1 was
from AUSTRAL Biologicals (San Ramon, CA). The cell
culture plates were from Becton Dickinson (Rutherford,
NJ), Falcon (Lincoln Park, NY), Corning (Corning, NY) and
Costar (Cambridge, MA). Luciferase assay system and
-galactosidase enzyme assay were purchased from
Promega (Tokyo, Japan). PathDetect Elk1 or cJun trans-
reporting system and N-terminal deleted constitutive active
MEKK1 (MEKK CA) were from STRATAGENE (La Jolla,
CA). PhosphoPlus p44/42 MAPK(Tyr204) antibody kit,
phosphospecific cJun antibody kit and specific MEK1
inhibitor (PD98059) were purchased from New England
Biolabs (Beverly, MA). All other reagents were obtained
from Sigma Chemical (St Louis, MO).CELL CULTURES
Chondrocytes were isolated from rat articular cartilage
as described previously.15 Isolated chondrocytes were cul-
tured in DMEM which contained 10% FBS, and passaged
once for the experiments. HepG2 cells were cultured with
RPMI containing 5% FBS.IN VITRO KINASE ASSAY OF ERK AND JNK
ERK and JNK activities were estimated by in vitro kinase
assay as described previously by our laboratory.17 Kinase
reaction was performed at 30°C for 30 min in the presence
of cold ATP together with Elk1 or cJun, which fused to GST
protein. Samples were subjected to SDS-PAGE, blotted
onto PVDF membranes, and immunoblotted with phospho-
specific Elk1 (Ser383) or phospho-cJun (Ser63) antibody.TRANS-REPORTER ASSAY OF ELK1 AND CJUN
Phosphorylation of Elk1 and cJun in vivo was quantified
by trans-reporting system as described previously.17 The
assay is designed to detect endogenous JNK and/or ERK
activity in vivo. The pFA-cJun or –Elk1 vector expresses a
fusion protein of the functional domain of c-Jun or Elk1
following GAL4 DNA binding domain. The reporter vector,
pFR-Luc contains a GAL4-response element upstream of
the luciferase gene. Phosphorylated Elk1 or cJun forms a
homodimer, leads to binding with GAL4 responsive ele-
ment, resulting in the activation of the reporter gene.P3TP LUCIFERASE ASSAY
Cultured rat articular chondrocytes and HepG2 with 80%
and 50% confluence, respectively, were transiently trans-fected by Lipofectin. Twenty-four hours later, the cells were
further incubated for 12 h with or without TGF. Cell
extracts were then prepared and subjected to luciferase
assay or -galactosidase assay as recommended by the
manufacturer.Results
SPECIFIC ACTIVATION OF ERK AND JNK BY TGF IN CRAC AND
HEPG2
We have previously demonstrated that ERK (but not JNK
or p38 MAP) was activated by TGF in CRAC.17 To
examine whether this specific activation is a cell type
specific phenomenon, we first compared the time-
dependent activation of ERK and JNK in response to TGF
by in vitro kinase assay in CRAC and HepG2. For this
purpose, kinase reaction was performed with immuno-
precipitated ERK or JNK and the specific substrate in the
presence of ATP. The phosphorylated substrate was
detected by immunoblotting with phospho-specific anti-
body. Similar to the previous experiments, treatment of
CRAC with TGF caused a rapid activation of ERK at
5 min, which reached a peak level at 15 min, while no
apparent activation of JNK was observed (Fig. 1A). In
contrast, in HepG2, activation of ERK could not be
detected. Instead, JNK was activated gradually with the
peak level recorded 1 h after TGF stimulation. The
specific activation of MAPK cascades by TGF was con-
firmed by the in vivo reporter assay. The expression vectors
of GAL4-Elk1 or c-Jun and GAL4 DNA binding domain
fused to the reporter gene were transiently transfected to
cells, followed by measurement of luciferase activity. In
CRAC, TGF stimulated the phosphorylation of Elk1, but
not c-Jun (Fig. 1B). In contrast, phosphorylation of both
Elk1 and c-Jun was stimulated by TGF in HepG2.PD98059, AN INHIBITOR OF MEK PREFERENTIALLY SUPPRESSED
TGF-INDUCED MEK–ERK PATHWAY IN CRAC
Since Elk1 could be a substrate of both JNK and ERK,
we used PD98059, an inhibitor of MEK that selectively
activates ERK in order to determine whether Elk1 phos-
phorylation observed in HepG2 was meditated through
ERK or JNK. For this, we first determined the optimal
concentrations of PD98059 for the inhibition of MEK activity
in CRAC. Incubation of PD98059 resulted in a dose-
dependent inhibition of in vitro kinase activity, in which
50 M concentration completely abolished TGF induced
ERK activation (Fig. 2A). Incubation of HepG2 with
PD98059, however, did not influence Elk-1 phosphoryl-
ation, while the phosphorylation of Elk1 was significantly
blocked in CRAC (Fig. 2B). Furthermore, PD98059 inhib-
ited 3TP-lux luciferase activity of CRAC but not of HepG2
(Fig. 2C). Considered together, these results indicate that
TGF transmits the signal though MEK-ERK-Elk1 pathway
in CRAC, while in HepG2, TGF transmits the signal
through JNK- mediated Elk1 and cJun pathways.DIVERGENT ACTION OF MEKK AND SEK ON 3TP-LUX ACTIVITY
BETWEEN CRAC AND HEPG2
To identify upstream transducers involved in TGF-
induced activation of ERK or JNK, several forms of MEKK
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3TP-lux. In CRAC, transfection of the wild or active form of
MEKK significantly inhibited TGF-induced 3TP activity,
whereby the inhibition was dominant in active MEKK1. On
the other hand, transfection of the kinase negative form of
MEKK1 or stress-activated protein kinase/ERK kinase 1
(SEK1) did not change the reporter activity (Fig. 3). In
HepG2 cells, overexpression of active MEKK1 resulted in a
strong activation of 3TP activity in both ligand-dependent
and independent induction, although wild MEKK1 did not
influence the activity. Transfection of dominant forms of
MEKK1 or SEK1, however, significantly diminished 3TP-
lux, especially in ligand-dependent activation. Theseresults indicate that in CRAC, ERK activation by TGF is
independent of MEKK1 or SEK1. In contrast, HepG2 cells
seem to require MEKK1 and SEK1 for TGF signaling.Fig. 1. TGF1 activates MAPK cascade in CRAC and HepG2. (A)
Time-dependent activation of ERK and JNK in CRAC and HepG2
in response to TGF1. CRAC and HepG2 were serum-derived for
24 h and stimulated with 5 ng/ml TGF1 for the indicated time
intervals. Equal amounts of total cell lysates were immunoprecipi-
tated with anti-phospho-ERK antibody or c-Jun conjugated sepha-
rose beads. In vitro kinase assays were performed at 30°C for
30 min using appropriate substrates as indicated. The samples
were then subjected to 10% SDS-PAGE and immunoblotted with
specific antibodies against phosphorylated forms of each sub-
strate. For a positive control in JNK assay, CRAC were irradiated
for 10 min with UV (25 J/m2). (B) Trans-reporting activation of Elk1
and c-Jun by TGF in CRAC and HepG2. Cells were cotransfected
with 100 ng/ml of pFA-Elk1 or pFA-c-Jun together with 500 ng/ml
of pFR-Luc and 150 ng/ml of pCMV5- galactosidase, cultured
with (solid bars) or without (open bars) 5 ng/ml TGF1 for 24 h,
and subsequently followed by measurement of luciferase activity.
Each bar represents the mean±SEM of six samples. Luciferase
activity is expressed relative to the control. Results are represen-
tative example of three independent experiments.Fig. 2. Effect of specific MEK inhibitor PD98059 on TGF1-induced
MAPK activation. (A) PD98059 inhibited TGF-induced ERK acti-
vation in CRAC in a dose-dependent manner. Cells were pre-
incubated with the indicated concentrations of PD98059 for 1 h
prior to stimulation by 10 ng/ml TGF. In vitro kinase assay was
performed using cell lysates prepared at 15 min after stimulation.
(B) PD98059 inhibited TGF-induced Elk1 phosphorylation of
CRAC but not of HepG2. Cells transfected with pFA-Elk1, pFR-Luc
and pCMV5- galactosidase were incubated with 50 M PD98059
together with (solid bars) or without (open bars) 5 ng/ml TGF for
24 h. Data are expressed as mean±SEM of relative activity
measured in six samples. (C) PD98059 inhibited TGF1-induced
3TP transcriptional activity in CRAC but not in HepG2. Cells
transfected with 500 ng/ml of p3TP-lux and 250 ng/ml of pCMV5-
galactosidase were incubated with the indicated concentrations of
PD98059 together with or without 5 ng/ml TGF. Bars represent
fold induction over the control values without TGF (N=4,
mean±SEM).NEGATIVE AND POSITIVE REGULATION OF 3TP-LUX ACTIVITY BY
TAK1 IN CRAC AND HEPG2
Another MEKK homologue, TAK1, also participates in
MAPK cascades. Therefore we studied the possible
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HepG2. In CRAC, transfection of the wild or negative form
of TAK1 did not significantly affect TGF-induced 3TP
activity in CRAC (Fig. 4). In contrast, cotransfection of wild
TAK1 with TAB1, an upstream activator of TAK1, resulted in
strong inhibition of ligand-induced activity. In HepG2, acti-
vation of TAK1 caused a diverse effect on 3TP-lux acti-
vation compared to CRAC. Transfection of kinase-negative
TAK1 decreased ligand-dependent 3TP induction, whereas
wild TAK1 or a combination with TAB1 increased both the
basal and fold induction. These results indicate that TAK1
also negatively and positively regulates TGF-induced
signaling in CRAC and HepG2, respectively.CROSS-TALK TO TGF-INDUCED SIGNAL TRANSDUCTION BY PKA
AND PKC PATHWAYS IN CRAC
We investigated the possibility of the cross-talk to the
TGF signaling pathway by PKA and PKC in CRAC. For
this purpose, 8-bromo-cyclic AMP and forskolin, a cAMP
analogue and stimulator of PKA, respectively, were used in
3TP-lux study. Incubation of CRAC with 8-bromo-cyclic
AMP or forskolin decreased 3TP activity in a dose-
dependent manner, although the inhibition was incomplete
(Fig. 5A and B). Calphostin C, a specific inhibitor of PKC
also partially decreased 3TP activity in a dose-dependentmanner (Fig. 5C). To confirm that the inhibition of TGF
signaling occurred at ERK level, we analyzed the kinase
activity of ERK by in vitro kinase assay. Pre-treatment with
calphostin C and forskolin for 1 h before TGF stimulation
significantly decreased the kinase activity of ERK (Fig. 5D).
These results indicate that PKA pathway negatively regu-
lates TGF signaling by inhibiting MAPK cascade involving
ERK, and that PKC activation through ERK activation is
required for TGF signaling in CRAC.Fig. 3. MEKK and SEK1 negatively regulated TGF1-induced 3TP
activity in CRAC, but positively regulated in HepG2. Equal
amounts of the indicated expression vector or empty pCMV5 were
transfected with 3TP-lux, and cells were incubated with (solid bars)
or without (open bars) TGF (5 ng/ml). Each bar represents the
mean±SEM of relative activity measured in six samples. Results
are representative example of one of three independent examples.
*P<0.01; Mann–Whitney U test. MEKK WT; wild type MEKK,
MEKK CA; constitutive active MEKK, MEKK DN; dominant nega-
tive MEKK, SEK DN; dominant negative SEK1.Fig. 4. TGF1 activated 3TP through TAK1-independent and
dependent pathways in CRAC and HepG2, respectively. Equal
amounts of the indicated expression vector or empty pCMV5 were
transfected with 3TP-lux, and the cells were incubated with (solid
bars) or without (open bars) 5 ng/ml TGF. Each bar represents
the mean±SEM of relative activity measured in six samples.
Results are representative example of one of three independent
examples. *P<0.01, **P<0.001; Mann–Whitney U test. TAK1 WT;
wild type TAK1, TAK1 DN; dominant negative TAK1, TAB1; wild
type TAB1.Discussion
In this study, we demonstrated that TGF transmits
intracellular signal molecules through two different mecha-
nisms in CRAC and HepG2 cells. In CRAC, in vitro kinase
assay and trans-reporting assay revealed that ERK, but not
JNK, of MAPK cascade was activated by TGF. In addition,
both 3TP luciferase induction and ERK activation were
blocked by PD98059. These results indicated that TGF
induced activation of the MEK–ERK pathway was required
for TGF signaling in CRAC. In HepG2 cells, however,
TGF activated JNK, but not ERK, in in vitro kinase assay.
Although both Elk1 and c-Jun were phosphorylated by
TGF in trans-reporting assay, the phosphorylation of
Elk1 could not be blocked by PD98059, suggesting that
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AMP or forskolin. CRAC transfected with 3TP-lux were incubated with the indicated concentrations of 8-bromo-cyclic AMP or forskolin, a
cAMP analogue or an adenylate cyclase stimulator, respectively, with or without TGF. Bars represent fold induction by TGF relative to the
control (N=4, mean±SEM). (C) Inhibition of TGF-induced 3TP activity by calphostin C. CRAC were pre-incubated in calphostin C, a specific
PKC inhibitor, at the indicated concentration 1 h prior to TGF stimulation. Data represent fold induction relative to the control (N=4,
mean±SEM). (D) Forskolin and calphostin C inhibit TGF-induced ERK activation. CRAC were pre-incubated in 10 M forskolin or 0.1 M
calphostin C for 1 h prior TGF stimulation, and in vitro kinase assay was performed using cell lysates prepared at the indicated time
intervals.Elk1 phosphorylation was caused by JNK activation.
Indeed, Elk1 has been confirmed to be a target of JNK as
well as ERK.18
The response of MAPK cascades to a variety of stimuli is
intricately regulated; however, these cascades could be
subgrouped into three families depending on the order of
activation: ERK, JNK and p38, which are the most down-
stream kinase, belong to MAPK. MEK, SEK and MKK
belong to MAP kinase (MAPKK), while Raf1, MEKK and
TAK1 belong to MAPKK kinase (MAPKKK).19–21 Our
results demonstrated that TGF signaling in CRAC does
not depend on MEKK1, TAK1 or SEK1. Dominant negative
forms of these expression vectors did not affect TGF-
induced 3TP activation. Moreover, although overexpres-
sion of wild and active forms of these molecules activated
the basal level of 3TP activity, the fold induction was
blocked by these vectors, suggesting that activation of
these kinases rather inhibit TGF signaling in CRAC. In
contrast, overexpression of dominant negative forms
MEKK1, TAK1 or SEK1 in HepG2 inhibited TGF induced
3TP-lux activation.We first demonstrated the regulation of JNK pathway by
MAPKKK in HepG2, in addition to the results of Atfi et al.22
showing the involvement of JNK activation in TGF signal-
ing. Considered together, our results suggest that TGF
transmits an intracellular signal, at least in part, through the
MEK–ERK pathway in CRAC, whereas activation of TAK1,
MEKK1, SEK1 and JNK is required for TGF signaling in
HepG2. Although our experiment did not identify the
upstream kinases necessary for the activation of the
MEK–ERK pathway in CRAC, c-Raf and/or Ras family may
be involved in TGF signaling. However, our preliminary
data suggested that overexpression of the dominant nega-
tive form of Ras (N17Ras) did not affect 3TP-lux luciferase
activity in CRAC (data not shown). In addition, wortmannin
phosphatidyl inositol 3-kinase inhibitor also had no effect on
3TP induction (data not shown).
TGF exhibits bidirectional effect on cell growth in CRAC
and in HepG2, respectively. We have previously demon-
strated that stimulation of CRAC with TGF (10 ng/ml) for
24 h increased [3H] thymidine incorporation by more than
seven-fold of control.23 On the other hand, HepG2 seems
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our independent experiment, TGF (10 ng/ml) decreased
the cell numbers of HepG2 to 60% of control, while CRAC
was increased to three-fold of control (data not shown). The
underlying mechanism by which TGF exerts the opposite
effect to cell growth is so far unclear; however, differential
activation of MAPK cascade depending on cell types might
be a possible explanation of multipotential activity of TGF.
Only HepG2 cells demonstrated the activation of JNK by
TGF but not by CRAC. Indeed, it has been demonstrated
in kidney distal tubule derived MDCK cells that TGF
induces apoptosis through JNK activation.26
The promoter region of 3TP-lux contains three copies of
TPA response element (TRE),27 binding sites for AP-1,
which is a transcriptional factor composed of c-Fos and
c-Jun. Recent studies showed that Smad3 could activate
TGF-induced transcription by binding directly with TRE.28
In addition, Smad3 interacts with c-Fos and c-Jun coopera-
tively with Smad4, resulting in a strong activation of 3TP
induction. A partial inhibition of 3TP-lux induction compared
with ERK kinase activity, even by high concentrations of
PD98059, probably means that a major part of TGF
signaling depends on the Smad pathway. We have pre-
viously demonstrated in CRAC that transactivation of the
c-fos gene by TGF requires a sis-inducible element (SIE),
a binding site for STATs, but not a serum response element
(SRE). These findings seem to contradict the requirement
of MEK–ERK pathway for TGF signaling, However,
together with our previous finding that TGF-induced cell
growth of CRAC was inhibited by PD98059,17 we consider
that in CRAC, the MEK–ERK pathway also plays an
important role in TGF signaling and subsequent cell
growth.
Our results also demonstrated that TGF signaling in
CRAC is regulated by PKA and PKC pathways through
cross-talk mechanisms. 8-bromo-cyclic AMP and forskolin,
a cAMP analogue and an adenylate cyclase activator,
respectively, inhibited 3TP-lux activity and transient acti-
vation of ERK induced by TGF. In addition, calphostin C,
a specific PKC inhibitor, also blocked 3TP-lux as well as
ERK activation. These results indicate that PKC pathway is
involved in TGF-induced 3TP-lux activation. In contrast,
PKA seems to act negatively in TGF-activated MAPK
cascade. Although the mechanism of cross-talk between
PKA and TGF signaling has not yet been clarified, it is
possible that c-Raf is a target molecule for PKA-dependent
negative regulation similar to the observation identified in
EGF-activated tyrosine kinase pathway.29,30 Further exper-
iments, including the Smad pathway and the upstream
MAPK cascade leading to the activation of ERK, are
required to identify the mechanisms in CRAC.
In conclusion, we have demonstrated in this study
that TGF transduces signals through PKC-dependent
MEK–ERK activation. MEKK1 inhibits TGF signaling;
however, this inhibition does not occur through SEK1 and
JNK. TAK1 is involved in TGF signaling. In contrast, in
HepG2, activation of MEKK1, SEK1, TAK1 and JNK is
required for TGF signaling.Acknowledgments
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ABBREVIATIONS
BMP: bone morphogenic protein
CDGF: cartilage-derived growth factor
CRAC: cultured rat articular chondrocytes
ERK: extracellular regulated kinase
JNK: c-Jun N-terminal kinase
MAPK: mitogen-activated protein kinase
MAPKKK: MAPK kinase kinase
MEK: MAPK/ERK kinase
MEKK1: MEK kinase 1
TGF: transforming growth factor 
